Ying Jin, Yongli Shan, Chunkai, Li, Annie X. An, Henry Q. Li, Davy X. Ouyang
With the continued rise of immunotherapy, it is becoming critically important to fully understand which immune cell lineages play a major role in mediating PD-1 response, in any given tumor microenvironment.
It is already well-known that anti-PD-1 antibodies work via activation of cytotoxic T cells. However, the contribution of other immune cell populations to PD-1 treatment are not well defined.
To understand how different lineages of immune cells impact PD-1 efficacy, we depleted various immune cell subpopulations in MC38, CT-26, and Hepa 1-6 murine syngeneic models when treated with PD-1 antibody, with the initial results presented here.
Your privacy is important to us.
We'll never share your information.